News Sentiment

JAZZ sentiment intelligence

Jazz Pharmaceuticals PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 247.53 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+1.5% over one week, +10.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 10.2% over four weeks
Fair value 80.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 7
Quartr 7
simplywall.st 7
PR Newswire 6
Investing.com Canada 3
Simply Wall Street 3
TradingView 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 25
Analyst action 6
Balance sheet 1
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Investing.com Canada Direct company coverage

Jazz Pharmaceuticals stock hits all-time high at 250.85 USD By Investing.com

Jazz Pharmaceuticals PLC's stock reached an all-time high of $250.85, marking a 114.77% increase over the past year. Despite a recent setback with its lung cancer drug Zepzelca failing a late-stage trial, the company maintains impressive gross profit margins and is considered und

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 16:11
Source
Investing.com Canada
Stock Titan Direct company coverage

Jazz Pharmaceuticals sets Aug. 3 webcast after market close

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and financi

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 20:18
Source
Stock Titan
PR Newswire UK Direct company coverage

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Jazz Pharmaceuticals plc announced it will report its second-quarter 2026 financial results on Monday, August 3, 2026, after the close of U.S. financial markets. The company's management will host a webcast at 4:30 p.m. ET to discuss the results and provide business and financial

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 20:15
Source
PR Newswire UK
Simply Wall Street Direct company coverage

Did Jazz’s Sleep and Oncology Pipeline Momentum Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative?

Jazz Pharmaceuticals is gaining investor attention due to its sleep-disorder and oncology portfolios, particularly with progress in its pipeline and franchise positioning. The company's investment narrative depends on its ability to leverage these franchises to offset patent clif

Tone
Positive 61/100
Event
Balance sheet
Published
19 Jul 2026 19:40
Source
Simply Wall Street
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Q1 2026 earnings summary

Jazz Pharmaceuticals (JAZZ) reported record Q1 2026 revenues of $1.1 billion, a 19% year-over-year increase, driven by strong growth in its sleep, epilepsy, and oncology portfolios. The company achieved a net income of $293.1 million, a significant improvement from a Q1 2025 net

Tone
Positive 87/100
Event
Earnings
Published
19 Jul 2026 02:11
Source
Quartr
Market source Direct company coverage

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run

Jazz Pharmaceuticals (JAZZ) has seen a significant 119.3% return over the past year, prompting an evaluation of its current valuation. Despite this strong performance, Simply Wall St's analysis suggests the stock appears undervalued on several measures, trading at a P/S ratio (3.

Tone
Positive 67/100
Event
Market update
Published
18 Jul 2026 11:09
Source
Market source
Simply Wall Street Direct company coverage

Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?

Jazz Pharmaceuticals (JAZZ) has shown strong share price performance and revenue growth, leading to a narrative that pegs it as 7.4% undervalued with a fair value of $257.00. This optimism stems from the expected approval and launch of new therapies, particularly within its oncol

Tone
Positive 66/100
Event
Earnings
Published
15 Jul 2026 00:45
Source
Simply Wall Street
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings summary

Jazz Pharmaceuticals reported record total revenue of $4.3 billion in 2025, a 5% increase year-over-year, with Q4 revenue reaching $1.2 billion, up 10%. Three of its franchises—rare sleep, rare epilepsy, and rare oncology—each surpassed $1 billion in annual revenue. The company a

Tone
Positive 75/100
Event
Earnings
Published
12 Jul 2026 20:40
Source
Quartr
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings summary

Jazz Pharmaceuticals (JAZZ) reported Q1 2025 revenues between $897.8M and $902M, driven by strong growth in Xywav and Epidiolex, despite declines in oncology and Xyrem. The company affirmed its 2025 revenue guidance of $4.15–$4.4 billion and expects Epidiolex to achieve blockbust

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 07:13
Source
Quartr
GuruFocus Direct company coverage

JAZZ Maintained by Deutsche Bank -- Price Target Raised to $270

Deutsche Bank has maintained a 'Buy' rating on Jazz Pharmaceuticals (JAZZ) and raised its price target from $250 to $270, indicating an 8% projected increase. Despite this positive analyst outlook, GuruFocus data suggests JAZZ is significantly overvalued by 63.5% based on its GF

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 21:10
Source
GuruFocus
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Status Update Summary

Jazz Pharmaceuticals' (JAZZ) Phase III IMforte trial demonstrated significant improvement in progression-free survival and overall survival for extensive-stage small cell lung cancer patients treated with lurbinectedin plus atezolizumab. This regimen is now positioned as a potent

Tone
Positive 86/100
Event
Market update
Published
09 Jul 2026 06:10
Source
Quartr
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary

Jazz Pharmaceuticals achieved record total revenues of $4.1 billion in 2024, a 6% year-over-year increase, with Q4 revenue reaching nearly $1.1 billion. Key growth drivers included Xywav and Epidiolex, and the company made significant progress in its R&D pipeline with FDA approva

Tone
Positive 82/100
Event
Earnings
Published
09 Jul 2026 05:41
Source
Quartr
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Q3 2024 earnings summary

Jazz Pharmaceuticals reported record Q3 2024 revenues of $1.05 billion, a 9% year-over-year increase, driven by strong sales of Xywav, Epidiolex, and Zepzelca. Net income rose significantly to $215.1 million, with adjusted EPS increasing by 37% to $6.61. The company affirmed its

Tone
Positive 71/100
Event
Earnings
Published
09 Jul 2026 05:41
Source
Quartr
Quartr Direct company coverage

Jazz Pharmaceuticals (JAZZ) Jefferies Global Healthcare Conference Summary

Jazz Pharmaceuticals shared an event summary from the Jefferies Global Healthcare Conference on July 8, 2026, highlighting significant progress in commercial activities, R&D, and corporate development, including the integration of Zymeworks and zanidatamab. The company provided a

Tone
Positive 86/100
Event
Market update
Published
09 Jul 2026 05:10
Source
Quartr
TradingView Direct company coverage

ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks

This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (JAZZ/N), providing details like market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return for each fund. The ETFs listed range acro

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:10
Source
TradingView
Stock Titan Direct company coverage

Jazz Pharmaceuticals (JAZZ) director Cozadd sells 6,000 shares via 10b5-1 trade

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026, at an average price of $240.47 per share, totaling $1.44 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted

Tone
Negative 38/100
Event
Market update
Published
07 Jul 2026 17:39
Source
Stock Titan
Finviz Direct company coverage

JAZZ - Jazz Pharmaceuticals plc Options

This article provides a detailed financial overview of Jazz Pharmaceuticals plc (JAZZ), including its last closing price, market capitalization, key financial ratios, EPS and sales growth rates, and various performance metrics. It also lists insider and institutional ownership, p

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 15:10
Source
Finviz
Simply Wall Street Direct company coverage

Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes

Jazz Pharmaceuticals (JAZZ) stock has broken out of a long-term trading base near an all-time high, driven by mixed news regarding its cancer drug Zepzelca and optimism surrounding Ziihera. Despite a 122.45% 1-year return, the company is considered 5.3% undervalued, with a fair v

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations

Jazz Pharmaceuticals' President & CEO, Renee D. Gala, had 4,835 ordinary shares withheld on June 30, 2026, to cover tax obligations from vested restricted stock units. This was a tax-withholding disposition at $237.72 per share, not an open-market sale. Following this transaction

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares

Jazz Pharmaceuticals' EVP and Chief Commercial Officer, Samantha Pearce, reported a tax-related disposition of 2,527 ordinary shares at $237.72 per share to cover tax obligations arising from the vesting of restricted stock units. This was a non-market transaction for tax withhol

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed

Jazz Pharmaceuticals' EVP & Chief Legal Officer, Neena M. Patil, had 2,678 ordinary shares withheld on June 30, 2026, to cover tax obligations arising from the vesting of restricted stock units (RSUs). This transaction, valued at $637,000 based on a reference price of $237.72 per

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding

Jazz Pharmaceuticals' EVP & CFO, Philip L. Johnson, reported a tax-withholding transaction where 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations on vesting restricted stock units. After this, he directly holds 56,431 shares. Additionally, Johns

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Stock Titan
FXEmpire Direct company coverage

Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?

Jazz Pharmaceuticals (JAZZ) has confirmed a bull flag breakout, with its stock closing above $243.32, reinforcing a long-term bullish trend. The stock's price activity indicates a higher swing low and successful test of the 50-day moving average, suggesting further upside potenti

Tone
Positive 80/100
Event
Guidance
Published
02 Jul 2026 20:40
Source
FXEmpire
Investing.com Direct company coverage

Jazz Pharmaceuticals stock hits all-time high at 243.39 USD

Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $243.46, trading just below its 52-week high of $243.32, marking a 132% surge from its 52-week low. This strong performance, reflected in a 121.3% one-year change, is supported by the company's impressive 91.5% gro

Tone
Positive 74/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Investing.com